Revolade (eltrombopag) is manufactured by GSK
Revolade (eltrombopag) is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts).
Revolade (eltrombopag) is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Revolade (eltrombopag) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
Revolade (eltrombopag) is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplantation.